Results 61 to 70 of about 53,302 (297)
ToxinsBotulinum toxin type A is a first-line treatment for post-stroke spasticity, with selective action at nerve endings and minimal effects beyond the injection site.
Alessandro Picelli +4 more
doaj +1 more source
The Hidden Burden of Hemifacial Spasm: A Systematic Review of Non‐Motor Symptoms
Movement Disorders Clinical Practice, EarlyView.Abstract Background Hemifacial spasm (HFS) is a chronic neurological disorder characterized by involuntary contractions of facial muscles. Traditionally regarded as a motor condition, HFS encompasses a spectrum of non‐motor symptoms that are often overlooked but significantly affect patients’ quality of life.
Miriam Carvalho Soares +2 more
wiley +1 more source
The role of the host—Neutrophil biology
Periodontology 2000, EarlyView., 2023 Abstract Neutrophilic polymorphonuclear leukocytes (neutrophils) are myeloid cells packed with lysosomal granules (hence also called granulocytes) that contain a formidable antimicrobial arsenal. They are terminally differentiated cells that play a critical role in acute and chronic inflammation, as well as in the resolution of inflammation and wound ...
Iain L. C. Chapple +4 more
wiley +1 more source
Botulinum toxin type A efficient treatment in patients with hemifacial spasm, Guantanamo 2018-2019
Revista Información Científica, 2020 Introduction: no research records were found addressing the results of the application of botulinum toxin type A in patients with hemifacial spasm in Guantanamo province.
Talía Marzo-Ramírez +1 more
doaj
Journal of Rehabilitation Medicine, 2018 OBJECTIVE To study the effect of therapeutic exercise on knee osteoarthritis after injection of botulinum toxin type A, hyaluronate or saline. METHODS Sixty participants with knee osteoarthritis were randomly assigned to 3 groups: injection of saline ...
X. Bao +5 more
semanticscholar +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz +2 more
wiley +1 more source
LifeBackground: Botulinum toxin type A is widely utilized for both therapeutic and aesthetic purposes, yet concerns regarding its immunogenicity have raised issues related to treatment failure and adverse reactions.
Kar Wai Alvin Lee +5 more
doaj +1 more source
Journal of Rehabilitation Medicine, 2017 Objective: Despite the widespread use of botulinum toxin in ambulatory children with spastic cerebral palsy, its value prior to intensive physiotherapy with adjunctive casting/orthoses remains unclear. Design: A pragmatically designed, multi-
Fabienne Schasfoort +8 more
doaj +1 more source
Toxins, 2018 A lumbar sympathetic ganglion block (LSB) is a therapeutic method for complex regional pain syndrome (CRPS) affecting the lower limbs. Recently, LSB with botulinum toxin type A and B was introduced as a novel method to achieve longer duration of ...
Yong-Seob Lee +5 more
semanticscholar +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Hyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT‐A). Real‐world evidence on treatment patterns remains limited. Objective This nationwide, population‐based study aimed to evaluate trends in BoNT‐A use in France between 2015 and 2023 ...
Marion Simonetta‐Moreau +3 more
wiley +1 more source